Pasithea Therapeutics Announces Positive Safety Review Committee Recommendation from its ...

KTTA Stock  USD 2.66  0.03  1.14%   
About 65% of all Pasithea Therapeutics' investors are looking to take a long position. The analysis of the overall investor sentiment regarding Pasithea Therapeutics Corp suggests that some traders are interested. The current market sentiment, together with Pasithea Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Pasithea Therapeutics stock news signals to limit their universe of possible portfolio assets.
  
-- SRC recommended that the trial escalate to the next dose level of 15mg capsule -- -- No dose-limiting toxicities observed to date -- -- No rash obse

Read at gurufocus.com
Gurufocus Stories at Macroaxis
  

Pasithea Therapeutics Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Pasithea Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Pasithea Therapeutics Fundamental Analysis

We analyze Pasithea Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pasithea Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pasithea Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Probability Of Bankruptcy

Probability Of Bankruptcy Comparative Analysis

Pasithea Therapeutics is currently under evaluation in probability of bankruptcy category among its peers. Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.

Pasithea Therapeutics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Pasithea Therapeutics stock to make a market-neutral strategy. Peer analysis of Pasithea Therapeutics could also be used in its relative valuation, which is a method of valuing Pasithea Therapeutics by comparing valuation metrics with similar companies.

Peers

Pasithea Therapeutics Related Equities

NTRBWNutriband Warrant   21.79   
0%
100.0%
VRAXVirax Biolabs   9.71   
0%
44.0%
ABVCABVC Biopharma   1.92   
0%
8.0%
RNXTRenovoRx   1.60   
0%
7.0%
KZRKezar Life   0.94   
0%
4.0%
REVBRevelation Biosciences   0.80   
0%
3.0%
KPRXKiora Pharmaceuticals   0.61   
0%
2.0%
KRONKronos Bio   1.04   
4.0%
0%
FBRXForte Biosciences   1.71   
7.0%
0%
MNOVMediciNova   2.30   
10.0%
0%
INDPIndaptus Therapeutics   5.41   
24.0%
0%
QNRXQuoin Pharmaceuticals   8.42   
38.0%
0%

Complementary Tools for Pasithea Stock analysis

When running Pasithea Therapeutics' price analysis, check to measure Pasithea Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pasithea Therapeutics is operating at the current time. Most of Pasithea Therapeutics' value examination focuses on studying past and present price action to predict the probability of Pasithea Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pasithea Therapeutics' price. Additionally, you may evaluate how the addition of Pasithea Therapeutics to your portfolios can decrease your overall portfolio volatility.
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
CEOs Directory
Screen CEOs from public companies around the world